REGULATORY

AMED Initiates “Middle Molecule Drug Discovery” Project; Aims to Out-License Lead Compounds to Drug Makers

June 25, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japan Agency for Medical Research and Development (AMED) will promote the development of “middle molecule drugs” in earnest. Few such drugs are under development in any country. AMED’s budget for FY2015 includes funding for a project to build a…

To read the full story

AMED to Build Library of Middle-Molecule Compound
June 22, 2015

REGULATORY

Japan Panel Clears Joenja, Dojolvi, Bayer MRI Contrast Agent
March 6, 2026
Japan Drug Prices to Fall 4% in FY2026 Revision: Official Gazette
March 5, 2026
Romiplate to See Steepest Cut in April Market Expansion Re-Pricing
March 5, 2026
MHLW Clarifies Use of Real-World Data in Drug Applications
March 5, 2026
MHLW Expands Eligibility for “Specific-Use Drug” Designation
March 5, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

G1 Rule to Hit Originator Biologics for First Time, Impact Seen for Up to 13 Brands

By Shinya Sato

Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…